With its first approved product, BioXcel Therapeutics, Inc. believes it has a differentiated treatment for agitation in schizophrenia and bipolar disorder patients, but the US Food and Drug Administration approval of Igalmi (BXCL501) announced on 6 April could be a way station on the path to bigger market opportunities for the sublingual film product in dementia and depression.
BioXcel Gets First Approval With Igalmi For Neuropsychiatric Agitation
Sublingual film product Igalmi is approved to treat agitation related to schizophrenia and bipolar disorder, but BioXcel also is targeting a bigger market opportunity in Alzheimer’s dementia.
More from New Products
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
More from Scrip
• By
The approval of another Novartis drug with a different mechanism means the company is further cornering multiple parts of IgAN pathogenesis.
• By
It might be the beginning of the end for the orphan drugs party but there is still sales growth enjoyment to be had for the sector, whose star performers are now looking increasingly like mainstream drugs.
• By
The German firm’s chairman, Hubertus von Baumbach, is adopting a ‘wait-and-see’ approach to the threat of pharma tariffs.